Interestingly, both high and low levels of MITF in melanomas have been linked with resistance to chemotherapeutic agents, increased invasiveness, and melanoma relapse after targeted therapy against BRAF mutations and MEK activity (Kemper et al., 2014; Müller et al., 2014; Wellbrock and Arozarena, 2015; Bai et al., 2019). Here, MITF is linked to melanoma.